AC
DSGN icon

Almitas Capital’s Design Therapeutics DSGN Stock Holding History

Almitas Capital’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3M Sell
1,530,335
-100
-0% -$1.01K 3.68% 5
2025
Q4 		$14.4M Hold
1,530,435
– – 3.16% 8
2025
Q3 		$11.5M Hold
1,530,435
– – 2.64% 6
2025
Q2 		$5.16M Buy
1,530,435
+77,539
+5% +$290K 1.3% 15
2025
Q1 		$5.61M Buy
1,452,896
+129,229
+10% +$617K 1.86% 7
2024
Q4 		$8.17M Hold
1,323,667
– – 1.79% 10
2024
Q3 		$7.12M Buy
1,323,667
+70,419
+6% +$331K 2.52% 10
2024
Q2 		$4.2M Buy
1,253,248
+227,180
+22% +$885K 1.75% 15
2024
Q1 		$4.14M Hold
1,026,068
– – 1.71% 19
2023
Q4 		$2.72M Buy
+1,026,068
New +$2.35M 0.94% 32

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Almitas Capital's DSGN Position: Q1 2026 in Review

Almitas Capital reduced its Design Therapeutics (DSGN) stake by 0.01% in Q1 2026, selling an estimated $1.01K and leaving 1,530,335 shares worth $16.3M. The position accounts for 3.68% of the portfolio, ranked #5.

Almitas Capital first reported a position in DSGN in Q4 2023 and has held it in 10 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Almitas Capital held 1,530,335 shares of Design Therapeutics worth $16.3M as of Q1 2026.
  • Almitas Capital sold 100 Design Therapeutics shares in Q1 2026, an estimated $1.01K.
  • Design Therapeutics made up 3.68% of Almitas Capital's portfolio in Q1 2026, its #5 holding.
  • Almitas Capital first reported a position in Design Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Almitas Capital's 13F filing for Q1 2026, filed 15 May 2026.